Alnylam and Inceptive Nucleics Join Forces to Advance RNAi Therapeutics with AI
A new partnership between Alnylam and Inceptive Nucleics, valued at up to $2 billion, aims to leverage AI foundation models to enhance RNA interference therapeutics over the next three years.
Editorial Staff about 3 hours ago